BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 10458773)

  • 21. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
    Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
    Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
    Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
    Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2.
    Lee SP; Thomas WA; Blake NW; Rickinson AB
    Eur J Immunol; 1996 Aug; 26(8):1875-83. PubMed ID: 8765034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
    Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
    Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4.
    Levitsky V; Zhang QJ; Levitskaya J; Masucci MG
    J Exp Med; 1996 Mar; 183(3):915-26. PubMed ID: 8642295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway.
    Lautscham G; Mayrhofer S; Taylor G; Haigh T; Leese A; Rickinson A; Blake N
    J Exp Med; 2001 Oct; 194(8):1053-68. PubMed ID: 11602636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease.
    Su Z; Peluso MV; Raffegerst SH; Schendel DJ; Roskrow MA
    Eur J Immunol; 2001 Mar; 31(3):947-58. PubMed ID: 11241300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide.
    Brooks JM; Murray RJ; Thomas WA; Kurilla MG; Rickinson AB
    J Exp Med; 1993 Sep; 178(3):879-87. PubMed ID: 7688791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens.
    Yang J; Lemas VM; Flinn IW; Krone C; Ambinder RF
    Blood; 2000 Jan; 95(1):241-8. PubMed ID: 10607708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide.
    Orentas RJ; Roskopf SJ; Nolan GP; Nishimura MI
    Clin Immunol; 2001 Feb; 98(2):220-8. PubMed ID: 11161978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4.
    Gavioli R; Kurilla MG; de Campos-Lima PO; Wallace LE; Dolcetti R; Murray RJ; Rickinson AB; Masucci MG
    J Virol; 1993 Mar; 67(3):1572-8. PubMed ID: 7679748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A recombinant adenovirus expressing an Epstein-Barr virus (EBV) target antigen can selectively reactivate rare components of EBV cytotoxic T-lymphocyte memory in vitro.
    Morgan SM; Wilkinson GW; Floettmann E; Blake N; Rickinson AB
    J Virol; 1996 Apr; 70(4):2394-402. PubMed ID: 8642667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Supermotif peptide binding and degeneracy of MHC: peptide recognition in an EBV peptide-specific CTL response with highly restricted TCR usage.
    Levitsky V; Liu D; Southwood S; Levitskaya J; Sette A; Masucci MG
    Hum Immunol; 2000 Oct; 61(10):972-84. PubMed ID: 11082510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of an human leucocyte antigen A2-restricted Epstein-Barr virus nuclear antigen-1-derived cytotoxic T-lymphocyte epitope.
    Marescotti D; Destro F; Baldisserotto A; Marastoni M; Coppotelli G; Masucci M; Gavioli R
    Immunology; 2010 Mar; 129(3):386-95. PubMed ID: 19922423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients.
    Whitney BM; Chan AT; Rickinson AB; Lee SP; Lin CK; Johnson PJ
    J Med Virol; 2002 Jul; 67(3):359-63. PubMed ID: 12116028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance.
    Khanna R; Burrows SR; Steigerwald-Mullen PM; Thomson SA; Kurilla MG; Moss DJ
    Virology; 1995 Dec; 214(2):633-7. PubMed ID: 8553567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity.
    Burrows SR; Silins SL; Khanna R; Burrows JM; Rischmueller M; McCluskey J; Moss DJ
    Eur J Immunol; 1997 Jul; 27(7):1726-36. PubMed ID: 9247584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A repetitive sequence of Epstein-Barr virus nuclear antigen 6 comprises overlapping T cell epitopes which induce HLA-DR-restricted CD4(+) T lymphocytes.
    Rajnavölgyi E; Nagy N; Thuresson B; Dosztányi Z; Simon A; Simon I; Karr RW; Ernberg I; Klein E; Falk KI
    Int Immunol; 2000 Mar; 12(3):281-93. PubMed ID: 10700463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Constructing TC-1-GLUC-LMP2 Model Tumor Cells to Evaluate the Anti-Tumor Effects of LMP2-Related Vaccines.
    Sun L; Hao Y; Wang Z; Zeng Y
    Viruses; 2018 Mar; 10(4):. PubMed ID: 29570629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.
    Fox CP; Haigh TA; Taylor GS; Long HM; Lee SP; Shannon-Lowe C; O'Connor S; Bollard CM; Iqbal J; Chan WC; Rickinson AB; Bell AI; Rowe M
    Blood; 2010 Nov; 116(19):3695-704. PubMed ID: 20671118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.